Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.61 |
| ▸ | THRA | P10827 | 17/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25773018 | 0.85 | THRB (0.71) | THRBTHRAESR1ESR2 | |
| SCHEMBL328377 | 0.85 | THRB (0.67) | THRBTHRAESR1ESR2 | |
| SCHEMBL4963467 | 0.82 | THRB (0.64) | THRBTHRAESR1ESR2 | |
| SCHEMBL1457668 | 0.82 | THRB (0.67) | THRBTHRAESR1ESR2 | |
| SCHEMBL27702889 | 0.82 | THRB (0.64) | THRBTHRAESR1ESR2 | |
| SCHEMBL4196760 | 0.82 | THRB (0.70) | THRBTHRAESR1ESR2 | |
| SCHEMBL12824810 | 0.81 | THRB (0.67) | THRBTHRAESR1ESR2 | |
| SCHEMBL4214385 | 0.80 | THRB (0.68) | THRBTHRA | |
| Hydrochloric Acid SCHEMBL1458369 | 0.80 | THRB (0.65) | THRBTHRAESR1ESR2 | |
| SCHEMBL10064689 | 0.80 | THRB (0.69) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRB 41/4885THRA 14/4885ESR1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.